Fortunately, the CGRP monoclonal antibodies used clinically for migraine are thought to have little effect on the immune system.10 In addition, a small tracking study following individuals with chronic migraine and MS who use CGRP inhibitors has not detected any worsening of MS symptoms.15 This evidence concerns the gene CALCA and myeloid sarcoma.